C. Portlock

2.3k total citations
36 papers, 1.6k citations indexed

About

C. Portlock is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, C. Portlock has authored 36 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pathology and Forensic Medicine, 14 papers in Oncology and 12 papers in Genetics. Recurrent topics in C. Portlock's work include Lymphoma Diagnosis and Treatment (27 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Viral-associated cancers and disorders (8 papers). C. Portlock is often cited by papers focused on Lymphoma Diagnosis and Treatment (27 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Viral-associated cancers and disorders (8 papers). C. Portlock collaborates with scholars based in United States, Germany and United Kingdom. C. Portlock's co-authors include Joachim Yahalom, Naomi R. Schechter, Ariela Noy, David J. Straus, Joseph R. Bertino, Howard Ozer, David W. Golde, Julie Teruya‐Feldstein, Harvey M. Golomb and A Fefer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

C. Portlock

36 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Portlock United States 21 1.1k 732 438 367 261 36 1.6k
R I Fisher United States 21 1.2k 1.1× 787 1.1× 441 1.0× 228 0.6× 300 1.1× 40 1.6k
Liliana Devizzi Italy 22 1.5k 1.4× 960 1.3× 478 1.1× 376 1.0× 456 1.7× 59 1.9k
B. Vaughan Hudson United Kingdom 24 1.5k 1.4× 830 1.1× 451 1.0× 522 1.4× 377 1.4× 36 1.9k
Fadhela Bouafia France 15 818 0.8× 668 0.9× 333 0.8× 255 0.7× 181 0.7× 24 1.5k
Xiaonan Hong China 20 930 0.9× 1.0k 1.4× 309 0.7× 416 1.1× 174 0.7× 71 1.7k
DC Linch United Kingdom 19 949 0.9× 720 1.0× 397 0.9× 174 0.5× 256 1.0× 37 1.5k
Hye Jin Kang South Korea 26 905 0.8× 822 1.1× 254 0.6× 461 1.3× 256 1.0× 120 1.8k
Natividad Neri Mexico 22 893 0.8× 952 1.3× 181 0.4× 226 0.6× 224 0.9× 70 1.6k
Isabelle Moullet France 15 795 0.7× 720 1.0× 300 0.7× 260 0.7× 203 0.8× 22 1.5k
Monica Balzarotti Italy 23 1.2k 1.1× 699 1.0× 402 0.9× 365 1.0× 545 2.1× 69 1.5k

Countries citing papers authored by C. Portlock

Since Specialization
Citations

This map shows the geographic impact of C. Portlock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Portlock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Portlock more than expected).

Fields of papers citing papers by C. Portlock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Portlock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Portlock. The network helps show where C. Portlock may publish in the future.

Co-authorship network of co-authors of C. Portlock

This figure shows the co-authorship network connecting the top 25 collaborators of C. Portlock. A scholar is included among the top collaborators of C. Portlock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Portlock. C. Portlock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Noy, Ariela, Heiko Schöder, Mithat Gönen, et al.. (2009). The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Annals of Oncology. 20(3). 508–512. 107 indexed citations
2.
Jacks, Lindsay M., Craig H. Moskowitz, Ariela Noy, et al.. (2009). Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Annals of Oncology. 21(3). 574–581. 15 indexed citations
3.
Schaffel, Rony, Cyrus V. Hedvat, Julie Teruya‐Feldstein, et al.. (2009). Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Annals of Oncology. 21(1). 133–139. 53 indexed citations
4.
Gerecitano, John F., C. Portlock, Paul A. Hamlin, et al.. (2008). A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas. Journal of Clinical Oncology. 26(15_suppl). 8512–8512. 7 indexed citations
5.
Moskowitz, Craig H., Paul A. Hamlin, Janice Gabrilove, et al.. (2007). Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Annals of Oncology. 18(11). 1842–1850. 33 indexed citations
6.
7.
Teruya‐Feldstein, Julie, Elizabeth Y. Chiao, D Filippa, et al.. (2004). CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Annals of Oncology. 15(11). 1673–1679. 157 indexed citations
8.
Portlock, C., Jing Qin, Nancy Roistacher, et al.. (2004). The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Annals of Oncology. 15(10). 1495–1503. 13 indexed citations
9.
10.
11.
Schechter, Naomi R., C. Portlock, & Joachim Yahalom. (1998). Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone.. Journal of Clinical Oncology. 16(5). 1916–1921. 221 indexed citations
12.
Gerdes, Hans, et al.. (1997). Endoscopic ultrasound in the evaluation of gastric small lymphocytic mucosa-associated lymphoid tumors.. Journal of Clinical Oncology. 15(5). 1761–1766. 45 indexed citations
13.
Castellino, R A, S Hilton, John P. OʼBrien, & C. Portlock. (1996). Non-Hodgkin lymphoma: contribution of chest CT in the initial staging evaluation.. Radiology. 199(1). 129–132. 26 indexed citations
14.
Yahalom, Joachim, Subhash C. Gulati, P. Maslak, et al.. (1993). Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.. Journal of Clinical Oncology. 11(6). 1062–1070. 99 indexed citations
15.
Golomb, Harvey M., Mark J. Ratain, A Fefer, et al.. (1991). Low Dose Interferon Alfa-2B for the Induction of Remission of Hairy Cell Leukemia: A Multi-institutional Study of 49 Patients. Leukemia & lymphoma. 5(5-6). 335–340. 2 indexed citations
16.
Golomb, Harvey M., A Fefer, David W. Golde, et al.. (1988). Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b.. PubMed. 15(5 Suppl 5). 7–9. 38 indexed citations
17.
Golomb, Harvey M., Mark J. Ratain, A Fefer, et al.. (1988). Randomized Study of the Duration of Treatment With Interferon Alfa-2B in Patients With Hairy Cell Leukemia. JNCI Journal of the National Cancer Institute. 80(5). 369–373. 48 indexed citations
18.
Krikorian, Jacqueline G., C. Portlock, & Peter Mauch. (1986). Hodgkin's disease presenting below the diaphragm: a review.. Journal of Clinical Oncology. 4(10). 1551–1562. 48 indexed citations
19.
Carman, M. D., et al.. (1984). Resistance to methotrexate due to gene amplification in a patient with acute leukemia.. Journal of Clinical Oncology. 2(1). 16–20. 116 indexed citations
20.
Jacobs, Charlotte, C. Portlock, & Saul A. Rosenberg. (1976). Prednisone in MOPP chemotherapy for Hodgkin's disease.. BMJ. 2(6050). 1469–1471. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R I Fisher Breakdown of academic impact, for papers by Liliana Devizzi Breakdown of academic impact, for papers by B. Vaughan Hudson Breakdown of academic impact, for papers by Fadhela Bouafia Breakdown of academic impact, for papers by Xiaonan Hong Breakdown of academic impact, for papers by DC Linch Breakdown of academic impact, for papers by Hye Jin Kang Breakdown of academic impact, for papers by Natividad Neri Breakdown of academic impact, for papers by Isabelle Moullet Breakdown of academic impact, for papers by Monica Balzarotti
Rankless by CCL
2026